Skip to main content
. 2021 May 1;10(9):1054–1063. doi: 10.1002/cpdd.937

Figure 2.

Figure 2

Mean rosuvastatin concentration‐time profiles after administration of rosuvastatin alone (PK day 1), coadministration with dabrafenib at initiation of dosing (PK day 8), and after repeat‐dose administration of dabrafenib at steady state (PK day 22). PK, pharmacokinetic.